 About Entrez
Text Version
Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM
Gateway
TOXNET
Consumer
Health
Clinical Alerts
ClinicalTrials.gov
PubMed
Central
|
 |
-
Comment in:
Antidepressant medication
use and breast cancer risk.
Cotterchio M, Kreiger
N, Darlington G, Steingart A.
Division of Preventive
Oncology, Cancer Care Ontario, Toronto, Canada.
Experimental and
epidemiologic studies suggest that antidepressant medication use may be
associated with breast cancer risk. This hypothesis was investigated
using a population-based case-control study; cases diagnosed in
1995-1996 were identified using the Ontario Cancer Registry, and
controls were randomly sampled from an Ontario Ministry of Finance
database. Data were collected using a self-administered questionnaire,
and multivariate logistic regression was used to estimate odds ratios
and 95% confidence intervals. Adjusted odds ratio estimates ranged from
0.7 to 0.8 and were not statistically significant for "ever" use of
antidepressants, tricyclics, and selective serotonin reuptake
inhibitors. Compared with no antidepressant use, use of tricyclic
antidepressants for greater than 2 years' duration was associated with
an elevated risk of breast cancer (odds ratio (OR) = 2.1, 95% confidence
interval (CI): 0.9, 5.0). Of the six most commonly reported
antidepressant medications, only paroxetine use was associated with an
increase in breast cancer risk (OR = 7.2, 95% CI: 0.9, 58.3). Results
from this study do not support the hypothesis that "ever" use of any
antidepressant medications is associated with breast cancer risk. Use of
tricyclic medications for greater than 2 years, however, may be
associated with a twofold elevation, and use of paroxetine may be
associated with a substantial increase in breast cancer
risk.
PMID: 10853633 [PubMed - indexed for MEDLINE]
|